NClip

Leukotriene Modifiers

3 min read

Leukotriene Modifiers

Key Points

  • Montelukast blocks leukotriene receptors to reduce airway inflammation and prevent asthma symptoms.
  • Zafirlukast and zileuton are additional oral leukotriene modifiers used as adjunct controllers.
  • This class is for long-term control, not rapid rescue during acute asthma attacks.
  • Main indications include asthma prevention, exercise-induced bronchospasm prevention, and allergic rhinitis.
  • Boxed warning: serious neuropsychiatric effects, including suicidal ideation.
  • Montelukast is commonly given in the evening for maintenance symptom control.
  • Zafirlukast and zileuton require caution/avoidance in hepatic impairment contexts.
  • Effect is delayed; therapeutic benefit may take about 3-7 days.

Mechanism of Action

Leukotriene modifiers reduce leukotriene-pathway signaling in the airways. Receptor antagonists (for example montelukast, zafirlukast) block leukotriene receptor effects, and synthesis inhibitors (for example zileuton) reduce leukotriene production. Net effect: lower airway inflammation, less bronchoconstriction, and reduced mucus burden.

Indications

  • Long-term control of asthma and reduction of asthma-attack frequency.
  • Prevention of exercise-induced bronchospasm.
  • Management of allergic rhinitis symptoms.

Nursing Considerations

  • Not a quick-relief medication for acute asthma attacks.
  • Available as granules, chewable tablets, and standard tablets.
  • Pediatric use: can be used in children 12 months and older per product criteria.
  • For exercise-induced symptoms, administer at least 2 hours before exercise.
  • Avoid using as first-line therapy for mild asthma when conventional treatment is effective, due to neuropsychiatric risk profile.
  • Assess baseline mood/behavior risk and monitor for new agitation, depression, hallucinations, or suicidality.
  • For montelukast maintenance, reinforce evening dosing consistency unless the prescriber specifies otherwise.
  • In zafirlukast/zileuton pathways, screen hepatic history and monitor liver-focused safety cues.

Boxed Warning: Neuropsychiatric Effects

Serious mental health adverse effects can occur, including suicidal ideation. Screen for mood and behavior changes and escalate concerns immediately.

Side Effects and Adverse Effects

  • Montelukast: Fever, headache, cough, abdominal pain, diarrhea, dizziness, epistaxis, urticaria.
  • Zafirlukast: Headache, nausea, vomiting, diarrhea, dizziness.
  • Zileuton: Nausea and sinusitis are common.
  • Class-level high-risk effect: Neuropsychiatric reactions (agitation, aggression, depression, suicidality).
  • Hepatic risk: Higher concern with zafirlukast/zileuton, especially in existing liver impairment.

Health Teaching

  • Take the medication at the same time each day.
  • For montelukast maintenance, take in the evening if instructed.
  • Do not stop therapy without discussing with the prescribing clinician.
  • Teach clients and family to report new agitation, mood change, sleep disturbance, depression, or suicidal thoughts immediately.
  • Reinforce that rescue inhalers (not montelukast) are used for sudden asthma symptoms.

Graph View